Skip to main content

Table 4 5-year RSR for CML patients from registry data stratified by region of origin and time period

From: Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000–2013

Source

Time period

5 Year RSR % (95 % CI)

Europe

2000–2002

33.8 (32.2–35.4)

 Sant et al. 2014 [34]

2003–2005

45.7 (43.9–47.5)

2006–2008

54.4 (52.5–56.2)

Eastern Europea

2000–2002

26.4 (22.4–30.6)

 Sant et al. 2014 [34]

2003–2005

28.6 (25.0–32.4)

2006–2008

35.3 (30.9–39.7)

Sweden

2001–2008

80 (75–83)

 Bjorkholm et al. 2011 [2]

Lithuania

2000–2004

33 (27–40)

 Our data

2005–2009

55 (47–60)

  1. aEastern Europe region: Lithuania, Estonia, Poland, Slovakia and Bulgaria